UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Researchers have found that CAR T-cell therapy can help aging intestines heal by targeting senescent cells. In mice, it boosted regeneration, reduced inflammation, and improved nutrient absorption, ...